Lance Lincoln, MD
Internal Medicine · Mountain Home, ARNPI 1649236290
Payments from drug & device makers
Across 143 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$427
- GSK$266
- Novartis$207
- Sumitomo Pharma America, Inc.$196
- Sunovion Pharmaceuticals Inc.$141
- Astellas Pharma US Inc$134
- plus $868 from 23 others
What the payments were for
- Food & beverage$2,240100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 32 | $427 |
| GSK | 19 | $266 |
| Novartis | 7 | $207 |
| Sumitomo Pharma America, Inc. | 13 | $196 |
| Sunovion Pharmaceuticals Inc. | 12 | $141 |
| Astellas Pharma US Inc | 9 | $134 |
| Novo Nordisk | 8 | $119 |
| Teva Pharmaceuticals USA, Inc. | 6 | $96 |
| Abbott | 6 | $84 |
| Bayer | 4 | $81 |
| Pfizer | 5 | $79 |
| AstraZeneca | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Exact Sciences | 2 | $30 |
| Edwards Lifesciences | 1 | $30 |
| Merck | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Sanofi | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$125
How this compares
$2,240 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $145,727 |
| EliquisApixaban | 199 | $142,463 |
| JardianceEmpagliflozin | 70 | $56,497 |
| XareltoRivaroxaban | 69 | $56,084 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $43,913 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $41,138 |
| GemtesaVibegron | 62 | $30,783 |
| TrulicityDulaglutide | 28 | $27,035 |
| MyrbetriqMirabegron | 43 | $26,645 |
| FarxigaDapagliflozin Propanediol | 21 | $22,383 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $21,743 |
| JanuviaSitagliptin Phosphate | 19 | $20,122 |
| MounjaroTirzepatide | 19 | $19,206 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $16,951 |
| Spiriva RespimatTiotropium Bromide | 22 | $15,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $79 | $148,654221 claims |
| Novo NordiskOzempic | $119 | $145,727127 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $23 | $72,28692 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $266 | $71,637108 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $15 | $46,24247 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $41 | $43,78373 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $196 | $30,78362 claims |
| Astellas Pharma US IncMyrbetriq | $134 | $26,64543 claims |
| MerckJanuvia | $29 | $20,12219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Mountain Home
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
- David PyleJonesboro$93K
- Manisha SinghLittle Rock$71K
- Govinda LohaniN Little Rock$55K
- Srikanth VallurupalliLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.